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Abstract 
Introduction: The novel coronavirus (COVID-19) has created great havoc across the whole world and now 
developing its deep roots in India also. From major metropolitan cities, the disease has reached rural areas of the 
country. In India most of the patients are asymptomatic and the mortality rate is very low. Objective: To do 
retrospective data analysis and to study time kinetics of recovery in asymptomatic COVID-19 patients. Methods: A 
total of 118 patients of COVID-19 admitted at R.D.B.P. Jaipuria hospital, Jaipur were recruited for this study. All 
were subjected to a detailed history, the clinical examination required hematological and biochemical investigations 
along with repeated RT-PCR test on nasopharyngeal swab samples at a regular interval according to guidelines of 
ICMR to detect COVID-19 antigen. All types of data and reports were computerized and analyzed. Results: In our 
study male sex was found to be much more affected (about 2.3 times) by coronavirus disease than that of the female 
sex. This male predominance was also found in the pediatric age group. Young adults and middle-aged adults 
constitute 79% of our study population of COVID-19 patients. It is also concluded that most patients (60%) in all 
age groups recovered in the first week. As age advances, recovery takes longer time than younger age groups. 
Recovery is not affected by sex. Asymptomatic patients who do not have any comorbidity have faster recovery from 
coronavirus disease than that of older patients with some comorbid condition.     
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Introduction  
 
Today the whole world is facing the pandemic of 
SARS CoV- 2 (COVID -19) which is the third and 
lethal outbreak of the corona virus group in the 21
st
 
century after SARS and MERS virus outbreaks in 2002 
and 2012 respectively. Corona viruses are a large group 
of viruses that cause illness both in humans and 
animals. This outbreak of novel corona virus disease 
was initially noticed in a seafood market in Wuhan city 
Hubei Province of China in mid of December 2019.    
__________________ 
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This outbreak was declared a Public Health Emergency 
of International Concern by the World Health 
Organization on 30 January 2020. On the same day, the 
first case of India of COVID-19 was detected in 
Kerala. Since then it has spread all over the country 
affecting the lacs of people and responsible for 
thousands of deaths in India till now. The currently 
available evidence for COVID-19 suggests that the 
causative virus has a zoonotic source and it is an 
enveloped RNA beta corona virus using angiotensin-
converting enzyme-2(ACE-2)  receptor for cell entry.  
COVID-19 is transmitted by respiratory droplets and 
fomites during close unprotected contacts between 
infector and infectee and also through contaminated 
surfaces. While around 80% of the patients of COVID-
19 are either asymptomatic or with mild illness only, 
around 15% develop severe disease requiring 
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hospitalization and oxygen support and about 5% are 
critically ill. Globally, it has been observed that males 
are affected about three times more in number than that 
of females and the pediatric age group is less prone to 
this infection. Autopsy findings in China and European 
countries showed endothelial damage of pulmonary 
vasculature, microvascular thrombosis, and 
hemorrhage linked to extensive alveolar and interstitial 
inflammation that ultimately result in COVID-19 
vasculopathy, pulmonary intravascular coagulopathy, 
ventilation-perfusion mismatch, and refractory ARDS. 
A reverse transcription-polymerase chain reaction (RT-
PCR) test is recommended to detect viral RNA for 
making the diagnosis of COVID-19.  Nasopharyngeal 
swab in viral transport medium (VTM) is the preferred 
sample with the maintenance of cold chain. The time 
duration in which patients of COVID-19 become 
negative for this swab test varies from person to 
person. This recovery time may be influenced by many 
factors like personal immunity, anemia, co-existence of 
any other infection, and presence of any co-morbidity 
like diabetes mellitus, hypertension, chronic heart 
diseases, and any addiction. 
 
Review of literature 
 KS- CHAN, and colleagues have shown in their study 
conducted at United Christian Hospital, Hongkong in 
2003 that “Age and comorbidity (eg: diabetes mellitus, 
heart disease) were consistently found to be significant 
independent predictors of various adverse outcomes in 
SARS.”As mentioned in the report of the WHO-China 
Joint Mission on Corona virus disease 2019 (COVID-
19)-using available preliminary data, the median time 
from onset to clinical recovery for mild cases is 
approximately 2 weeks and 3-6 weeks for patients with 
the severe critical disease [1]. A study conducted in 
Singapore in March 2020 by Monira Mollazehi and 
others shows that younger patients recover faster than 
elderly patients. The results tell that the hazard rate of 
recovery time from COVID-19 infection will increase 
by 1% as the age of patient increase by one year. In a 
study conducted at the University of California San-
Francisco by Elizabeth Fernandez, it was found that 
among people infected with corona virus, the risk of 
disease progression in those who currently smoke or 
previously smoked was nearly double than of that of 
non- smokers. 
Objectives 
To do retrospective analysis of demographic data, 
hematological and biochemical investigation reports of 
asymptomatic COVID-19 patients. 
To study time kinetics of recovery in COVID-19 
asymptomatic patients. 
To know the relation of co-morbidities with the 
recovery time of COVID-19 Patients. 
Material and methods  
Study design 
This would be a Hospital-based retrospective data 
analytical and observational study. R.D.B.P. Jaipuria 
Government Hospital was declared as a designated 
treatment center for asymptomatic COVID-19 patients 
by the Government of Rajasthan. For symptomatic and 
critically ill patients of COVID-19 other hospitals were 
assigned in the city by the government (2). The study 
was approved by hospital administration and ethics 
committee clearance has been obtained for conduction 
of the study and publication of the report.     
Chief medical and health officer of Jaipur, Rajasthan 
appointed a team that has done cluster and random 
sampling at the community level in the containment 
zone and hot spot area of COVID-19 in Jaipur. 
Asymptomatic positive cases (RT-PCR test positive in 
nasopharyngeal swab) were referred to R.D.B.P. 
Jaipuria hospital for further evaluation and 
management. 
Study size 
                              A total of 118 patients of COVID-19 were taken for 
the study who were admitted in R.D.B.P. Jaipuria 
hospital, Jaipur in the month of April-May 2020. All 
these patients were included for demographic profile 
analysis. Out of these, 9 symptomatic patients were 
referred to a higher center. Rest 109 asymptomatic 
COVID-19 patients were recruited for further study. 
Methodology 
In this case series, asymptomatic 118 patients of 
COVID-19, admitted in the hospital were subjected to 
a detailed history, clinical examination, and routine 
investigations (complete blood counts, random blood 
sugar, blood-grouping, and urine complete 
examination). Required special investigations like liver 
function test, renal function test, chest X-ray, and blood 
sugar fasting and post-prandial were also done. 
Repeated RT-PCR tests for COVID-19 were performed 
on nasopharyngeal swab samples at the required 
interval for all 109 patients excluding referrals who 
became symptomatic and were excluded from further 
study.  Hydroxychloroquine 400 mg and Azithromycin 
500 mg daily were prescribed to all the Patients 
according to guidelines of the government of India (3). 
‘Recovery’ from COVID-19 was confirmed when two 
consecutive swab samples taken at 24 hours interval 
were found negative for viral antigen by RT-PCR test. 
All types of data and investigation reports were 
computerized and analyzed by appropriate statistical 
methods. 
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Inclusion criteria 
 All Patients below 70 years of age who were 
admitted to our hospital as asymptomatic cases of 
COVID-19. 
 
Exclusion Criteria 
 Pregnant women 
 Symptomatic patients of COVID-19 (for purpose of 
studying time kinetics of recovery) 
Observations 
Table 1: Demographic Profile of COVID-19 Patients 
 
Value No. 
Total patients 118 
Patient referred  9 
Patient treated 109 
Sex Distribution  
Male 82 
Female 36 
Children (n) 12 
(M) 10 
(F) 2 
Religion (n)  
Hindu 30 
Muslim 88 
Other 0 
 
Table 2: Hematological profile and other variables of asymptomatic COVID-19 patients 
Value Mean SD 
Age (yrs.) 34.4. 13.3 
Days of recovery (days)  7.21  5.82 
Average days of Recovery (days)   
1
st
 week 2.92 2.02 
2
nd
 week 12.34 1.91 
3
rd
 week 17.90 1.83 
   
Hb (g/dL) 12.85 1.67 
TLC (x 10
6 
/L) 7.288 2.124 
Neutrophils (%) 55.80 8.93 
Lymphocyte (%) 39.47 10.65 
Platelets (x10
6
/dL) 2.34 0.85 
B. Sugar (g/dL) 94.4 40.5 
SGOT (U/L) 29.2 10.9 
SGPT (U/L) 29.72 18.9 
S. Bilirubin (Total) (mg/dl) 0.84 0.36 
S. Bilirubin (Direct) (mg/dl) 0.46 0.15 
S. Urea (mg/dl) 21.34 5.5 
S. Creatinine (mg/dl) 0.88 0.18 
S. Total Protein (g/dl) 6.77 0.73 
S. Albumin (g/dl) 4.44 1.57 
S. BP (mmHg) 123 10 
D. BP (mmHg) 80 6 
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Table 3: Age distribution of asymptomatic COVID-19 patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Sex distribution of COVID-19 (asymptomatic) patients 
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Figure 1: Total No. of COVID-19 positive (asymptomatic) case 
Age Total no of case % 
<1 yr 1 1% 
1-5 yr 1 1% 
6-10 yr 6 5% 
11-15 yr 4 3% 
16-20 7 6% 
21-25 yr 10 8% 
26-35 yr 35 30% 
36- 45 yr 30 25% 
46- 55 yr 19 16% 
 56-65 yr 4 3% 
>65 yr 1 1% 
 
118 100% 
 
 
No. % 
Male 82 70% 
Female 36 30% 
Total 118 100% 
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Table 5: Sex Distribution of COVID-19 (children) patients 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Time kinetics of recovery in Asymptomatic COVID-19 patients 
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Figure 2: Time Kinetics of recovery in COVID-19 patient 
(asymptomatic) 
No. of patients %  
Table 5: Sex Distribution in COVID-19 children (asymptomatic)  
 
No. % 
Male 10 83% 
Female 2 17% 
Total 12 100% 
Table 6: Time of virus recovery in COVID-19 patients (asymptomatic) 
Time No. of patients Percentage % 
≤1 week 66 60% 
≤2 week 32 30% 
≤3 week 11 10% 
Total 109 100% 
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Table 7: Time kinetics of recovery of COVID-19 patients (asymptomatic) in Weeks: Age-wise distribution  
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Figure 3: Time Kinetics of Recovery in COVID-19 
patients (asymptomatic) 
No. of cases in 1st week No. of cases in 2nd week No. of cases in 3rd week 
Age 
1st 
Week 
% (cases 
in age 
group) 
2nd 
week 
% (cases 
in age 
group) 
3rd 
week 
% (cases 
in age 
group) 
Total 
Patients 
<1 yrs. 1 100% 0 0% 0 0% 1 
1-5 yrs. 1 100% 0 0% 0 0% 1 
6-10 yrs. 3 100% 0 0% 0 0% 3 
11-15 yrs. 3 75% 1 25% 0 0% 4 
16-20 yrs. 6 86% 1 14% 0 0% 7 
21-25 yrs. 5 50% 5 50% 0 0% 10 
26-35 yrs. 19 63% 5 17% 6 20% 30 
36- 45 yrs. 18 60% 9 30% 3 10% 30 
46- 55 yrs. 9 50% 7 39% 2 11% 18 
56-65 yrs.  1 25% 3 75% 0 0% 4 
>65 yrs. 0 0% 1 100% 0 0% 1 
Total 66 
 
33 
 
11 
 
109 
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Figure 4: % cases recovery in each age groups of 
COVID-19 positive (asymptomatic) patients 
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Figure 5: Recovery of COVID-19 patients 
(asymptomatic) in First week 
1st Week % (in age group) 
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Table 8: Time recovery of asymptomatic COVID-19 patients according to Sex 
 
 
 
 
 
 
 
 
 
Table 9: Time kinetics of recovery in COVID-19 patients (asymptomatic) with comorbidities 
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Figure 8: Time of recovery (% cases) accroding to Sex 
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Table 8: Time of Recovery of COVID-19 patients (asymptomatic) according to sex 
 
1st 
week 
%  
(1 week) 
2nd 
week 
% 
(2
nd
 week) 
3rd 
week 
% 
(3
rd
 week) Total 
Male 
(n=78) 48 62% 24 31% 6 8% 78 
Female 
(n=31) 18 58% 8 26% 5 1% 31 
Total 66 
 
32 
 
11 
 
109 
Table 9: Time recovery in (asymptomatic) COVID-19 patients with comorbidities 
 
n 
1st 
week 
% cases 
1
st
 
week 
2nd 
week 
% cases 
2
nd
 
week 
3rd 
week 
% cases 
3
rd
 
week 
Comorbidity 7 3 43% 4 57% 0 0% 
No Comorbidity 102 63 62% 28 28% 11 11% 
Total 109 66  32  11  
Comorbidity: Hypertension, Diabetes Mellitus, Hypothyroidism, alcoholism 
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Discussion 
 
In our study of demographic profile, out of a total of 
118 patients, 82 patients (70%) were males while 36 
patients (30%) were females (Table 1&5). It has been 
observed worldwide that males are much more affected 
in number than that of females by COVID-19. Chang 
D and Lin M have shown in their study that 77% of 
COVID-19 patients are males [4].  In our study 
population, 12 patients were of the pediatric age group. 
Among them, 2 (17%) were females while 10 (83%) 
were males (Table 4), so in children also male 
predominance is found. Wei M and colleagues have 
resulted in his study that among children, the male 
infection rate (60.95%) is higher than that of females 
(39.05%) [5]. The mean age of the affected population 
was 34.4 (± 13) years in our study (Table 1). In our 
study population, different age groups were- Children 
0-20years (16% of the total study group), Young adults 
21-25 years (8%), 26-35 years (30%), middle-age 
adults 36-55 years (41%), and >55 years (old adults) 
were only 4% of the study population (Table 3 & 
Figure 1). Lechien et.al reported the initial experience 
of 1420 patients in Europe from France, Belgium, 
Spain, and Switzerland. The mean age was 39±12 
years, 94% were less than 60 years of age [6]. It is 
observed that young adults (38% of our study 
population) and middle-aged adults (41% of the study 
population) are more affected by COVID-19 than that 
of children and old age people. This can be explained 
by the reason that these age groups are more exposed 
because they tend to work outside the home, go out to 
fulfilling domestic requirements, etc.  In hematological 
findings of asymptomatic COVID-19 patients (Table 
2), their mean hemoglobin was 12.85gm% (±1.67), and 
the mean WBC count was 7,200 (±2,124) and was in 
the normal range. These results are synchronous with 
the study of De Chang[7]. In our study lymphocytosis 
was found only in 34% of patients while in differential 
leukocyte count, the mean lymphocyte percentage was 
39.47% (±10.65). These results are contradictory to 
findings of Sina Vaqili and others who have found 
lymphopenia in COVID-19 patients in their literature 
review[8]. Thrombocytopenia was found only in 17% 
cases of our study group and the mean value of platelet 
count in our study was 2.34 lacs/c.mm (±0.85). 
Panyang XU has mentioned in his article note that 
statistics from 41 patients of COVID-19 at a designated 
hospital in Wuhan, 5% of patients had 
thrombocytopenia on admission [9]. 
In our study of asymptomatic COVID-19 patients, 
random blood sugar levels, liver function tests, and 
kidney function tests were in normal limits. We didn’t 
measure s. ferritin level, IL-6 levels, and S. 
procalcitonin levels. 
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Figure 9: Case recovery (% cases) in asymptomatic COVID-
19 patients with comorbidities 
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In the analysis of time kinetics of recovery of 109 
asymptomatic COVID-19 cases, 66 patients (60%) 
became RT-PCR test negative in one week, 32 patients 
(30%) recovered in two weeks and the rest of the 11 
patients (10%) had their recovery during the third week 
of admission (Table 6 & Figure 2).  The mean recovery 
time of our study group of asymptomatic patients of 
COVID-19 was 7.2 (±5.8) days (Table 2). In the study 
of De Chang, the median recovery time (days from 
virus positivity to virus negativity) was 5.5 days (7). 
Irena Voinsky and et.al. have mentioned in their study 
the average recovery time of between 13 to 14 days in 
symptomatic patients of COVID-19, lowest for women 
under 19 years and highest for men aged 50-59 years 
respectively [10]. As mentioned in table 7 and Figure 
3,4,5,6&7  among all asymptomatic patients, most of 
the children (0-15 years) recovered within one week 
(89%). In the age group 16-20 yrs., 86% recovered 
during the first week. Similarly, 50% of patients of 21-
25 years age gr.,63% of 26-35 years age gr, 60% of 36-
45 years of age gr,50% of 46-55 age gr and 25% of 56-
65 years age group recovered with-in one week of 
treatment.  On the other hand, the percentage of 
patients recovering during the second-week were 11% 
in children ( 0-15 yrs), 14% of age group 16-20 yrs., 
50% of 21-25 yrs age, 17% in the age group 26-35 yrs., 
30% in the age group 36- 45 yrs., 39%  in 46- 55 yrs., 
75% in the age group 56-65 yrs. and in >65 yrs.  100% 
gained recovery in the second week. We also observed 
that patients recovered in the third week are mostly 
young adults (26-35 yrs.) and middle age groups (36-
55 yrs.) patients. Based on these observations, it can be 
concluded that as the age advances patients of COVID-
19 take a longer time to recover from the disease.  This 
recovery pattern is synchronous with the findings of 
Irena Voinsky in his study (10). However, this trend 
was not found in elderly patients >65 yrs., maybe 
because only one patient of this age was there in our 
study. This may be due to the fact that we were 
admitting only asymptomatic cases and most of the 
patients suffering from COVID-19 of the elderly age 
group tend to have symptoms. 
As depicted in table 8 and figure 8, we have not found 
any significant difference in the recovery time of males 
and females. However, this finding is contradictory to 
the results of Irena Voinsky who found early recovery 
in females [10]. The impact of comorbidities 
(hypertension, diabetes mellitus, hypothyroidism, 
alcoholic liver disease) over the recovery time of 
asymptomatic COVID-19 patients is evident in our 
study as shown in table 9 & figure 9. In our study 43% 
of patients belonging to comorbid groups recovered in 
the first week while 62% of patients without any co-
morbidities recovered in the first week. 57% of patients 
with comorbidities recovered in the second week while 
in the non-comorbid group 28% recovered in two 
weeks. And rest 11% of patients with no comorbidity 
recovered in the third week. Thus, it can be understood 
that even asymptomatic comorbid patients of COVID-
19 take a longer time for recovery than that of non-
comorbid patients. Sanyaolu A. et al. concluded that 
diabetes, hypertension, and hyperlipidemia were the 
most common comorbidities associated with COVID-
19[11].  Wei-Jie Guan and et al. have observed in their 
study that among laboratory-confirmed cases of 
COVID-19 patients with any comorbidity yielded 
poorer clinical outcomes than those without[12]. A big 
limitation of our study is that only asymptomatic 
COVID-19 patients are recruited for the study. The 
small sample size is also a limiting factor.  Thus, there 
is a need for a larger and vast study including 
symptomatic and critically ill patients to explore the 
less understood areas of this novel coronavirus disease.       
 
Conclusion 
 
It is concluded from our study that among patients of 
COVID-19 disease, male patients are affected more 
than that of female patients (males 2.3 times more 
affected than females). Similarly, male children are 
more prone to COVID-19 disease than female children 
(males 5 times more than females). Young adults and 
middle-aged persons are the most affected age group 
by this disease. Hematological and biochemical 
profiles of asymptomatic COVID-19 patients are not 
altered, however, thrombocytopenia and lymphocytosis 
are found in a small percentage of patients which may 
not be statistically significant.   It has been observed in 
our study that younger patients recover faster than that 
of older patients. Recovery from COVID 19 is not 
affected by the sex of the patient. Presence of 
comorbidity slower the speed of recovery even in 
asymptomatic COVID-19 patients. The comorbidities 
had not affected and caused severity with multi-organ 
dysfunctions in our patients thus it has not 
compounded the natural course of the virus and its 
disease in humans. Our analysis was done on 
asymptomatic COVID-19 positive patients (confirmed 
by RT-PCR), hence time kinetics of recovery in these 
patients has revealed the dynamics of this emerging 
SARS-CoV2 virus in humans as a natural progression 
of infection in humans.  
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